Pharmafile Logo
Pharmafocus logo
Advanced Search

NICE

Showing 15 posts of 866 posts found.

Soliris image

NICE approves world’s most expensive drug

January 28, 2015
Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris

The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …

News
Xarelto image

NICE recommends Bayer heart attack drug

January 26, 2015
Sales and Marketing ACS, Bayer, J&J, JJ, NICE, Xarelto, q4, rivaroxaban

NICE has recommended Xarelto in final draft guidance as an option for preventing blood clots in people who have had …

News
J&J image

Olysio and Xarelto boost J&J’s Q4

January 21, 2015
Sales and Marketing J&J, JJ, Janssen, NICE, Remicade, Velcade, Xarelto, financials, hep C, olysio, q4, quarter four

Johnson & Johnson earned a 10% increase in worldwide sales of its drugs in the last quarter of 2014 compared …

News

CDF chair: more treatment reviews to come

January 16, 2015
Sales and Marketing CDF, Cancer Drugs Fund, NHS, NHS England, NICE, peter clark

The chair of NHS England’s cancer drugs fund has said there is likely to be more reviews of affordable treatments …

News
Olysio image

Janssen privy to new pricing scheme and see NICE nod

January 16, 2015
Sales and Marketing Janssen, NHS, NICE, hep C, hepatitis, olysio, ribavirin, simeprevir

Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing …

News
Sovaldi image

NICE approves Sovaldi

January 16, 2015
Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi

NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …

News

NICE releases reflux disease guidelines

January 15, 2015
Sales and Marketing NHS, NICE, UK, gor, gord, h2ra

NICE has released new guidelines providing doctors with advice on how to treat gastro-oesophageal reflux disease (GORD) in young people. …

News
dendreon image

Another NICE no for Dendreon cancer drug

January 13, 2015
Sales and Marketing Cancer, Dendreon, FDA, NHS, NICE, Provenge, sipuleucel-T

Dendreon has seen its prostate cancer treatment for people whose disease has spread and who are not yet suitable for …

News
AZ image

AstraZeneca drops CDF application

January 12, 2015
Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib

AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …

News
Sativex image

Late-stage failure for Otsuka and GW cancer pain drug

January 9, 2015
Sales and Marketing Cancer, Epidiolex, GW, MS, NICE, Otsuka, Sativex, cannabidiol, nabiximols

Otsuka and GW Pharmaceutical’s multiple sclerosis drug Sativex has failed to meet the primary endpoint in its first Phase III …

News
Afinitor image

Exclusive: Novartis drug struck off cancer drugs fund

January 8, 2015
Sales and Marketing Afinitor, Jevtana, NHS, NHS England, NICE, Novartis, Sanofi, everolimus

Novartis’ Afinitor (everolimus) will be removed from the Cancer Drugs Fund list when NHS England announces which drugs it can …

News
Entyvio image

NICE rejects Takeda Crohn’s disease drug

December 23, 2014
Sales and Marketing Crohn’s disease, Entyvio, NHS, NICE, Takeda, crohn's disease, vedolizumab

Takeda has seen its treatment for people with Crohn’s disease Entyvio rejected by NICE in an initial appraisal. The healthcare …

News
Janssen image

Janssen launches HIV combination pill

December 17, 2014
Research and Development, Sales and Marketing BMS, Gilead, HIV, Janssen, NHS, NICE, rezolsta, tybost

Janssen has launched its HIV therapy Rezolsta in the UK, which combines its own Prezista with Gilead’s Tybost. Prezista (darunavir) …

News
Pradaxa image

Boehringer gets NICE nod for Pradaxa

December 16, 2014
Sales and Marketing Boehringer, NHS, NICE, Pradaxa, VTE, dagibatran, ingelheim, warfarin

NICE has confirmed a recommendation for Boehringer Ingelheim’s controversial anti-blood clotting drug Pradaxa, as a treatment for blood clots in …

News
Inlyta image

NICE backs Pfizer’s drug for advanced kidney cancer

December 16, 2014
Sales and Marketing NICE, Pfizer, Sutent, Votrient, Zytiga, axitinib, inlyta, xofigo

UK healthcare guidance body NICE has issued final draft guidance recommending Pfizer’s Inlyta for advanced kidney cancer. The draft recommendation …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026